These findings indicate that a reduction in tumor proliferation does not always align with tumor shrinkage, implying that anatomic response does not necessarily reflect a favorable molecular biological response to NACT treatment in ER+/HER2- breast cancer. Here, ERBB2 is linked to breast cancer.